Serial Entrepreneur Nazli Azimi to Present in Translational Biotechnology Seminar Series



From Bench to Bedside: An Entrepreneurial Journey

Nazli Azimi, PharmD, PhD

Former Founder and CEO
Board Member
Bioniz Therapeutics

Wednesday, April 27, 2022
1:00 - 2:00 pm

Webinar Registration

Dr. Azimi holds a PharmD and PhD in pharmaceuticals. She completed a post-doctoral fellowship in Immunology at the National Institutes of Health with a focus on cytokine biology. She is the author of over 30 peer-reviewed publications in the areas of immunology, oncology, virology, and neurological disease. She is the co-inventor of a technology that covers over 50 patents. Her early roles include Staff Scientist for the National Cancer Institute and National Institutes of Health and Assistant Professor at the Fred Hutchinson Cancer Research Center in the Virology program. Dr. Azimi is a biotechnology entrepreneur with a track record of launching biopharmaceutical companies that transform innovative scientific concepts into platform technologies for discovery of novel medicines. In her latest role, Dr. Azimi was the founder, President and CEO of Bioniz Therapeutics where she led the discovery and clinical development of first-in-class molecules for treatment of auto-immune/inflammatory diseases and cancer. The company was acquired in February 2022.

This seminar will be conducted in an interactive environment where Dr. Azimi will initiate the conversation by telling her story and encourage the audience to participate.

  seminar flyer and contact information

Alex Zhavoronkov from Insilico Medicine to Present in Translational Biotechnology Seminar Series



End-to-end AI for Drug Discovery

Alex Zhavoronkov, PhD

Founder and CEO
Insilico Medicine

Wednesday, April 20, 2022
1:00 pm – 2:00 pm

Webinar Registration

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions.

In this seminar, Dr. Zhavoronkov will present traditional drug discovery and success examples of how AI can improve the process

  seminar flyer and contact information

Alireza Sohrabi from University of Texas, Austin to Present in Translational Biotechnology Seminar Series



3D Printed Scaffolds toward Personalized Medicine in Glioblastoma

Alireza Sohrabi, Ph.D.
Postdoctoral Researcher
Bioengineering Department
University of Texas, Austin

Tuesday, April 19, 2022
3:00 pm – 4:00 pm

Webinar registration

Dr. Sohrabi earned his B.Sc in polymer science and engineering from the University of AmirKabir in Iran. He moved to the Netherlands to continue his education, where he earned his M.Sc. in chemical engineering from the University of Twente. In 2014, he joined the bioengineering department at UCLA, working under Professor Stephanie Seidlits's mentorship. He earned his Ph.D. in bioengineering in 2021. Alireza started his postdoctoral research in the same lab in June 2021 and later moved to the University of Texas at Austin to continue his research. Alireza's primary research involves engineering biomaterial to study how the tumor microenvironment affects glioblastoma (GBM) cancer. Currently, he is working on a novel targeted nano-capsule gene carrier for gene delivery in GBM.

This seminar will discuss the biomaterial-based culture system developed by the Seidlits lab to grow patient-derived GBM cells in a brain-mimetic 3D scaffold and expand on a rather limited understanding of GBM tumors. The Seidlits lab utilized this platform to elucidate the pathway behind the development of drug resistance in GBM cells. Next, the speaker will discuss the provisional patent their group has obtained based on a combination of the biomaterial platform and the 3D printing technologies they've employed and discuss the thought process behind expanding an idea to a patent.

  seminar flyer and contact information

Department Chair John Carpten to Chair President Biden’s National Cancer Advisory Board

President Joe Biden has appointed Dr. Carpten to serve as chair of the administration’s National Cancer Advisory Board, which plays an important role in guiding the director of the National Cancer Institute in setting the course for the national cancer research program. 


White House Press Release

USC News

Translational Genomics Concluded Genomic Diversity and Human Disease Lecture Series

We wish to thank all our speakers for bringing their expertise and engaging in candid discussions with students throughout the semester.  Please see full list of lectures here. 

Department Chair Dr. Carpten Kicked Off Translational Genomics Virtual Distinguished Lecture Series


USC Translational Genomics:
Accelerating Improvements in Healthcare at USC KSOM through Intentional Integration between Basic Discovery Research and Clinical Science

John D. Carpten, PhD
Professor, USC Department of Urology
Chair, USC Department of Translational Genomics
Director, USC Institute for Translational Genomics
Director, USC Molecular Genomics Core
Co-Leader, Norris Comprehensive Cancer Center

Tuesday, August 18, 2020
11:00 am – 12:00 pm

In 2016, the USC Department of Translational Genomics was created under the leadership of the founding chair John Carpten, PhD with co-leadership by Vice Chair Dr. David Craig.  The mission of USC Translational Genomics is to help the Keck School of Medicine realize its full potential in improving patient outcomes through the intentional integration of basic and clinical research.  The foundational components of our department include genome science and biomedical informatics.  The department currently includes eight faculty members dedicated to scholarship, teaching and education, and service to the community.  The department hosts several major grants and is focused on translating genomic discoveries into new knowledge that may someday have clinical application.  The department also contributes to the educational mission of the university through its master’s degree programs in Translational Biotechnology and Translational Biomedical Informatics.   Diversity is also a major component of our departmental foundation, including being among the world leaders in research studies that aim to understand the relationship between population differences and disease incidence and outcomes, and in our intentional goals for biomedical workforce diversity.

  seminar flyer and contact information
  presentation slides:      Deck 1           Deck 2